242 related articles for article (PubMed ID: 22589534)
1. Discovery of a novel allosteric modulator of 5-HT3 receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site.
Trattnig SM; Harpsøe K; Thygesen SB; Rahr LM; Ahring PK; Balle T; Jensen AA
J Biol Chem; 2012 Jul; 287(30):25241-54. PubMed ID: 22589534
[TBL] [Abstract][Full Text] [Related]
2. 5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor.
Newman AS; Batis N; Grafton G; Caputo F; Brady CA; Lambert JJ; Peters JA; Gordon J; Brain KL; Powell AD; Barnes NM
Br J Pharmacol; 2013 Jul; 169(6):1228-38. PubMed ID: 23594147
[TBL] [Abstract][Full Text] [Related]
3. Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT3 receptors.
Gasiorek A; Trattnig SM; Ahring PK; Kristiansen U; Frølund B; Frederiksen K; Jensen AA
Biochem Pharmacol; 2016 Jun; 110-111():92-108. PubMed ID: 27086281
[TBL] [Abstract][Full Text] [Related]
4. Novel mechanism of modulation at a ligand-gated ion channel; action of 5-Cl-indole at the 5-HT
Powell AD; Grafton G; Roberts A; Larkin S; O'Neill N; Palandri J; Otvos R; Cooper AJ; Ulens C; Barnes NM
Br J Pharmacol; 2016 Dec; 173(24):3467-3479. PubMed ID: 27677804
[TBL] [Abstract][Full Text] [Related]
5. Activation of human 5-hydroxytryptamine type 3 receptors via an allosteric transmembrane site.
Lansdell SJ; Sathyaprakash C; Doward A; Millar NS
Mol Pharmacol; 2015 Jan; 87(1):87-95. PubMed ID: 25338672
[TBL] [Abstract][Full Text] [Related]
6. Modular design of Cys-loop ligand-gated ion channels: functional 5-HT3 and GABA rho1 receptors lacking the large cytoplasmic M3M4 loop.
Jansen M; Bali M; Akabas MH
J Gen Physiol; 2008 Feb; 131(2):137-46. PubMed ID: 18227272
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in 5-HT3 receptor pharmacology.
Thompson AJ
Trends Pharmacol Sci; 2013 Feb; 34(2):100-9. PubMed ID: 23380247
[TBL] [Abstract][Full Text] [Related]
8. The L293 residue in transmembrane domain 2 of the 5-HT3A receptor is a molecular determinant of allosteric modulation by 5-hydroxyindole.
Hu XQ; Lovinger DM
Neuropharmacology; 2008 Jun; 54(8):1153-65. PubMed ID: 18436267
[TBL] [Abstract][Full Text] [Related]
9. Exploring a potential palonosetron allosteric binding site in the 5-HT(3) receptor.
Del Cadia M; De Rienzo F; Weston DA; Thompson AJ; Menziani MC; Lummis SC
Bioorg Med Chem; 2013 Dec; 21(23):7523-8. PubMed ID: 24128813
[TBL] [Abstract][Full Text] [Related]
10. Discriminating between 5-HT₃A and 5-HT₃AB receptors.
Thompson AJ; Lummis SC
Br J Pharmacol; 2013 Jun; 169(4):736-47. PubMed ID: 23489111
[TBL] [Abstract][Full Text] [Related]
11. Auto-inhibition at a ligand-gated ion channel: a cross-talk between orthosteric and allosteric sites.
Hu XQ
Br J Pharmacol; 2015 Jan; 172(1):93-105. PubMed ID: 25176133
[TBL] [Abstract][Full Text] [Related]
12. Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan.
Nakamura Y; Ishida Y; Yamada T; Kondo M; Shimada S
J Neurochem; 2013 Apr; 125(1):7-15. PubMed ID: 23305320
[TBL] [Abstract][Full Text] [Related]
13. A conserved cysteine residue in the third transmembrane domain is essential for homomeric 5-HT3 receptor function.
Wu DF; Othman NA; Sharp D; Mahendra A; Deeb TZ; Hales TG
J Physiol; 2010 Feb; 588(Pt 4):603-16. PubMed ID: 19933756
[TBL] [Abstract][Full Text] [Related]
14. A triad of residues is functionally transferrable between 5-HT
Mosesso R; Dougherty DA
J Biol Chem; 2018 Feb; 293(8):2903-2914. PubMed ID: 29298898
[TBL] [Abstract][Full Text] [Related]
15. Palonosetron-5-HT
Price KL; Lillestol RK; Ulens C; Lummis SC
ACS Chem Neurosci; 2016 Dec; 7(12):1641-1646. PubMed ID: 27656911
[TBL] [Abstract][Full Text] [Related]
16. Agonists and antagonists induce different palonosetron dissociation rates in 5-HT₃A and 5-HT₃AB receptors.
Lummis SC; Thompson AJ
Neuropharmacology; 2013 Oct; 73():241-6. PubMed ID: 23747573
[TBL] [Abstract][Full Text] [Related]
17. Conformational Changes in the 5-HT
Munro L; Ladefoged LK; Padmanathan V; Andersen S; Schiøtt B; Kristensen AS
Mol Pharmacol; 2019 Dec; 96(6):720-734. PubMed ID: 31582575
[TBL] [Abstract][Full Text] [Related]
18. Superagonist, Full Agonist, Partial Agonist, and Antagonist Actions of Arylguanidines at 5-Hydroxytryptamine-3 (5-HT
Alix K; Khatri S; Mosier PD; Casterlow S; Yan D; Nyce HL; White MM; Schulte MK; Dukat M
ACS Chem Neurosci; 2016 Nov; 7(11):1565-1574. PubMed ID: 27533595
[TBL] [Abstract][Full Text] [Related]
19. 5-HT(3) receptors.
Lummis SC
J Biol Chem; 2012 Nov; 287(48):40239-45. PubMed ID: 23038271
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a 5-HT
Price KL; Lummis SCR
ACS Chem Neurosci; 2018 Jun; 9(6):1409-1415. PubMed ID: 29508995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
